Acta neurologica Scandinavica
-
Acta Neurol. Scand. · Sep 1992
Six-year follow-up study on the efficacy and safety of vigabatrin in patients with epilepsy.
Twenty-five patients with epilepsy (mostly with partial seizures) who had responded favourably to a short-term trial of add-on vigabatrin entered maintenance treatment. After 52 to 78 months, 15 patients continue to take the drug with good therapeutic response. ⋯ In most patients, side effects were absent or mild, the most frequent complaint being weight gain. It is concluded that the antiepileptic efficacy and good clinical tolerability of vigabatrin are generally maintained during long-term treatment for up to 6 years.
-
Acta Neurol. Scand. · Sep 1992
Case ReportsCarbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma.
Valproic acid induced coma is presented in an adult patient without a history of metabolic disease. Liver biopsy revealed a reduction in activity of carbamyl phosphate synthetase-I, an enzyme obligated for transformation of ammonia to urea in the urea cycle. After recovery CT scan follow-up showed marked cerebral atrophy which did not exist prior to the state of coma. Risk factors are discussed.